I agree. Please NO reverse split. Allows to be shorted heavier and the company to do a secondary to further dilute. Who knows, something will get the price back to $1. The market cap of this stock just seems ridiculously undervalued.
I wrote Eric Powers about delisting from Nasdaq. He did get back to me this morning. Here is his response...
Our apologies for the delay in response. In answer to your question about the potential for CLBS delisting from NASDAQ, NASDAQ’s process includes a deficiency notice, sent after 30 consecutive days of the stock being under $1.00. In our case, this has not yet been received but we would expect it in early February. Following that notice, the company has 180 days to comply. To comply, the company’s share price must trade above the minimum for at least 10 consecutive days in the 180-day period. We are closely monitoring the situation and will take action to address this deficiency at the appropriate time.
- Eric Powers
And a reverse split generally means a secondary is coming diluting shares. Reverse splits are disastrous in the biotech world.
I lean towards being positive, no big selling to start off the year. Maybe, a lot are wait and see. When movement does start, lets hope upward b/c right now it does not take much to move the PPS.
I see Mazzo(CEO) just bought 20,000 shares at $1.14. Although it is not a lot compared to his salary, no one throws away money if they see something not good coming down the pipeline. A good sign, IMO.
The shareholders were absolutely obliterated during her tenure. However, she was paid well for sure. If her performance is rated on the share price, no more needs to be said. This company needs some good news to help the shareholder.
I totally agree with you on high failure rate on trials. PPS is low enough for me to see what happens.
Sentiment: Strong Buy
This PPS should be floating around $2 right now. A very good entry point at this price. PCT division and revenue put a floor on the PPS. Huge upside potential with the current trials, etc., limited downside risk. Hoping for no more dilution or at least at much higher PPS.
Sentiment: Strong Buy
Its not a loss until you sell it. Not a lot of institutional money in this company. Stocks are valued completely on current performance/execution(debt, revenue, monetization, assets, cash burn, etc.) and expectations(current and upcoming trials, etc.). Stocks that are perceived "cheap" due to low price generally get cheaper. Hoping for something good to happen.
Just like tele transportation in star trek, its something we all want, is it reality? Is it ever going to be reality? Michael J Fox Foundation used to be the biggest support of stem cell research due to his Parkinson's. You know how much support now they give to stem cell research.....NONE!! Be wary of any stem cell research having any meaningful results. Look at STEM, CUR, etc.....all headed to ZERO! CLBS(formally NBS) has had THREE 1/10 reverse splits. 15 year all time low. Management has been constantly been accused of exaggerated results and botched tests!
How do you know so much and able to make sure claims on easy approval? Other than cord blood for certain specified indications—there are no approved stem cell products by the FDA. Do you work for CLBS?